title: The Role of Radiotherapy in Acromegaly.
abstract: Radiotherapy has, historically, played a central role in the management of acromegaly, and the last 30 years have seen substantial improvements in the technology used in the delivery of radiation therapy. More recently, the introduction of highly targeted radiotherapy, or 'radiosurgery', has further increased the therapeutic options available in the management of secretory pituitary tumors. Despite these developments, improvements in primary surgical outcomes, an increase in the range and effectiveness of medical therapy options, and long-term safety concerns have combined to dictate that, although still deployed in selected cases, the use of radiotherapy in the management of acromegaly has declined steadily over the past 2 decades. In this article, we review some of the main studies that have documented the efficacy of pituitary radiotherapy on growth hormone hypersecretion and summarize the data around its potential deleterious effects, including hypopituitarism, cranial nerve damage, and the development of radiation-related intracerebral tumors. We also give practical recommendations to guide its future use in patients with acromegaly, generally, as a third-line intervention after neurosurgical intervention in combination with various medical therapy options.
authors.affiliation: Department of Endocrinology, St. Bartholomew's Hospital, London, UK.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Hannon
authors.forename: Ariel L
authors.initials: AL
authors.lastname: Barkan
authors.forename: William M
authors.initials: WM
authors.lastname: Drake
mesh_terms: D000172:Acromegaly; D000236:Adenoma / Q000532:radiotherapy*; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D007018:Hypopituitarism / Q000532:radiotherapy*; D010911:Pituitary Neoplasms / Q000532:radiotherapy*; D016634:Radiosurgery / Q000379:methods
chemical_list: D019382:Human Growth Hormone